Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The dTAG system for immediate and target-specific protein degradation.

Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong KK, Gray NS, Bradner JE.

Nat Chem Biol. 2018 May;14(5):431-441. doi: 10.1038/s41589-018-0021-8. Epub 2018 Mar 26.

2.

Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.

Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS, Bradner JE.

Nat Chem Biol. 2018 Apr;14(4):405-412. doi: 10.1038/s41589-018-0010-y. Epub 2018 Mar 5.

3.

Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.

Ishoey M, Chorn S, Singh N, Jaeger MG, Brand M, Paulk J, Bauer S, Erb MA, Parapatics K, Müller AC, Bennett KL, Ecker GF, Bradner JE, Winter GE.

ACS Chem Biol. 2018 Mar 16;13(3):553-560. doi: 10.1021/acschembio.7b00969. Epub 2018 Jan 29.

PMID:
29356495
4.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS.

Cell Chem Biol. 2018 Jan 18;25(1):88-99.e6. doi: 10.1016/j.chembiol.2017.10.005. Epub 2017 Nov 9.

5.

MELK is not necessary for the proliferation of basal-like breast cancer cells.

Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS.

Elife. 2017 Sep 19;6. pii: e26693. doi: 10.7554/eLife.26693.

6.

HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WG Jr.

Sci Transl Med. 2017 Jul 12;9(398). pii: eaal5272. doi: 10.1126/scitranslmed.aal5272.

7.

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE.

Mol Cell. 2017 Jul 6;67(1):5-18.e19. doi: 10.1016/j.molcel.2017.06.004. Epub 2017 Jun 29.

8.

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.

Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, Dastjerdi S, Wühr M, Dhe-Paganon S, Armstrong SA, Bradner JE.

Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743. doi: 10.1002/anie.201611281. Epub 2017 Apr 18.

9.

Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors.

Zhao L, Dunne CE, Clausen DJ, Roberts JM, Paulk J, Liu H, Wiest OG, Bradner JE, Williams RM.

Isr J Chem. 2017 Apr;57(3-4):319-330. doi: 10.1002/ijch.201600130. Epub 2017 Jan 27.

10.

Transcription control by the ENL YEATS domain in acute leukaemia.

Erb MA, Scott TG, Li BE, Xie H, Paulk J, Seo HS, Souza A, Roberts JM, Dastjerdi S, Buckley DL, Sanjana NE, Shalem O, Nabet B, Zeid R, Offei-Addo NK, Dhe-Paganon S, Zhang F, Orkin SH, Winter GE, Bradner JE.

Nature. 2017 Mar 9;543(7644):270-274. doi: 10.1038/nature21688. Epub 2017 Mar 1.

11.

Design and characterization of bivalent BET inhibitors.

Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE.

Nat Chem Biol. 2016 Dec;12(12):1089-1096. doi: 10.1038/nchembio.2209. Epub 2016 Oct 24.

12.

Impact of Altered Medication Administration Time on Interdisciplinary Bedside Rounds on Academic Medical Ward.

Young E, Paulk J, Beck J, Anderson M, Burck M, Jobman L, Stickrath C.

J Nurs Care Qual. 2017 Jul/Sep;32(3):218-225. doi: 10.1097/NCQ.0000000000000233.

PMID:
27611580
13.

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF, Hammerman PS, Brown M, Cichowski K, Long H, Bradner JE, Wong KK.

Cancer Discov. 2016 Sep;6(9):1006-21. doi: 10.1158/2159-8290.CD-16-0164. Epub 2016 Jun 16.

14.

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE.

Nat Med. 2016 Jun;22(6):632-40. doi: 10.1038/nm.4092. Epub 2016 May 2.

15.

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.

Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA.

Science. 2016 Mar 11;351(6278):1214-8. doi: 10.1126/science.aad5214. Epub 2016 Feb 11.

16.

Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling.

Chou DH, Vetere A, Choudhary A, Scully SS, Schenone M, Tang A, Gomez R, Burns SM, Lundh M, Vital T, Comer E, Faloon PW, Dančík V, Ciarlo C, Paulk J, Dai M, Reddy C, Sun H, Young M, Donato N, Jaffe J, Clemons PA, Palmer M, Carr SA, Schreiber SL, Wagner BK.

J Am Chem Soc. 2015 Jun 24;137(24):7929-34. doi: 10.1021/jacs.5b04284. Epub 2015 Jun 15.

17.

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE.

Science. 2015 Jun 19;348(6241):1376-81. doi: 10.1126/science.aab1433. Epub 2015 May 21.

18.

Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MAS, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL.

Cell Rep. 2015 Feb 10;10(5):755-770. doi: 10.1016/j.celrep.2015.01.017. Epub 2015 Feb 5.

19.

An unbiased approach to identify endogenous substrates of "histone" deacetylase 8.

Olson DE, Udeshi ND, Wolfson NA, Pitcairn CA, Sullivan ED, Jaffe JD, Svinkina T, Natoli T, Lu X, Paulk J, McCarren P, Wagner FF, Barker D, Howe E, Lazzaro F, Gale JP, Zhang YL, Subramanian A, Fierke CA, Carr SA, Holson EB.

ACS Chem Biol. 2014 Oct 17;9(10):2210-6. doi: 10.1021/cb500492r. Epub 2014 Aug 11.

20.

A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.

Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, Shamji AF, Wagner BK, Schreiber SL.

ACS Chem Biol. 2012 Jul 20;7(7):1152-7. doi: 10.1021/cb300139y. Epub 2012 Apr 30.

21.

Encodable activators of SRC family kinases.

Zellefrow CD, Griffiths JS, Saha S, Hodges AM, Goodman JL, Paulk J, Kritzer JA, Schepartz A.

J Am Chem Soc. 2006 Dec 27;128(51):16506-7.

PMID:
17177392
22.

Musical skill in dementia: a violinist presumed to have Alzheimer's disease learns to play a new song.

Cowles A, Beatty WW, Nixon SJ, Lutz LJ, Paulk J, Paulk K, Ross ED.

Neurocase. 2003 Dec;9(6):493-503.

PMID:
16210231
23.

ES Views: National Network for Environmental Education.

Paulk J.

Environ Sci Technol. 1988 Jan 1;22(1):25-7. doi: 10.1021/es00166a603. No abstract available.

PMID:
22195503

Supplemental Content

Support Center